Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders

Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders

Abstract Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response is highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate the amount of var...

Full description

Bibliographic Details
Main Authors: C. Okhuijsen-Pfeifer, M. Z. van der Horst, C. A. Bousman, B. Lin, K. R. van Eijk, S. Ripke, Y. Ayhan, M. O. Babaoglu, M. Bak, W. Alink, H. van Beek, E. Beld, A. Bouhuis, M. Edlinger, I. M. Erdogan, A. Ertuğrul, G. Yoca, I. P. Everall, T. Görlitz, GROUP (Genetic Risk and Outcome of Psychosis) investigators, K. P. Grootens, S. Gutwinski, T. Hallikainen, E. Jeger-Land, M. de Koning, M. Lähteenvuo, S. E. Legge, S. Leucht, C. Morgenroth, A. Müderrisoğlu, A. Narang, C. Pantelis, A. F. Pardiñas, T. Oviedo-Salcedo, J. Schneider-Thoma, S. Schreiter, E. Repo-Tiihonen, H. Tuppurainen, M. Veereschild, S. Veerman, M. de Vos, E. Wagner, D. Cohen, J. P. A. M. Bogers, J. T. R. Walters, A. E. Anil Yağcıoğlu, J. Tiihonen, A. Hasan, J. J. Luykx
Format: Article
Language:English
Published: Nature Publishing Group 2022-04-01
Series:Translational Psychiatry
Online Access:https://doi.org/10.1038/s41398-022-01884-3

Internet

https://doi.org/10.1038/s41398-022-01884-3

Similar Items